Description

1. Product Overview: Nexataf® is an antiviral formulation containing Tenofovir Alafenamide, used for the treatment of chronic Hepatitis B infection and suppression of HBV viral replication.

2. Composition: Tenofovir Alafenamide Fumarate INN 25 mg | Dosage Form: Tablet

3. Pharmacological Class: Nucleotide Reverse Transcriptase Inhibitor (NtRTI)

4. Mechanism of Action: Tenofovir Alafenamide is a prodrug of tenofovir that inhibits HBV reverse transcriptase enzyme, blocking viral DNA replication and reducing viral load in infected liver cells.

5. Indications: Chronic Hepatitis B virus (HBV) infection | Management of HBV-associated liver disease

6. Dosage & Administration: As directed by physician or hepatology specialist only | Oral use | Usually taken once daily with food

7. Clinical Benefits: Reduces HBV viral load | Improves liver function | Slows progression of liver disease | Lowers risk of cirrhosis and hepatocellular carcinoma

8. Contraindications: Hypersensitivity to Tenofovir Alafenamide or any component of the formulation

9. Precautions: Regular monitoring of liver and kidney function required | Risk of HBV flare-up if discontinued abruptly | Use cautiously in renal impairment

10. Drug Interactions: May interact with strong P-glycoprotein inducers such as rifampin and certain anticonvulsants

11. Special Populations: Use in pregnancy and lactation only if clearly needed and prescribed | Pediatric use under specialist guidance

12. Adverse Effects: Headache | Nausea | Fatigue | Abdominal discomfort | Rare renal or bone effects

13. Storage Conditions: Store below 30°C | Protect from light and moisture | Keep out of reach of children

14. Packaging: Tablet blister pack

15. Manufacturer: Everest Pharmaceutical Ltd.